| ■ 영문 제목 : Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2023-2027 | |
![]() | ■ 상품코드 : IRTNTR72723-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2023년 2월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 약120 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (24시간 이내) ■ 조사대상 지역 : 북미, 유럽, 아시아 태평양, 기타 지역 ■ 산업 분야 : 의료 |
| Single User (1명 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| Technavio사의 본 연구 보고서에 따르면 세계의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모가 2022년에서 2027년 사이에 1,657.08백만 달러에 이르며, 예측 기간 동안 연평균 12.92% 성장할 것으로 전망하고 있습니다. 본 조사 보고서는 세계의 BCL-2 (B 세포 림프종 2) 억제제 시장에 대해 조사 및 분석을 실시하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 제품별 (병용 요법, 단독 요법) 분석, 종류별 (미만성 대세포형 B세포림프종 (DLBCL), 여포성 림프종, 만성 림프성 백혈병, 맨틀 세포 림프종 (MCL)) 분석, 고객 현황, 지역별 현황 (북미, 아시아 태평양, 유럽, 중동 및 아프리카, 남미, 미국, 중국, 독일, 영국, 일본) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 조사 보고서는 Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma 등의 기업 정보가 포함되어 있습니다. ・개요 ・시장 현황 ・시장 규모 예측 ・과거 시장 규모 ・Five Force 분석 ・세계의 BCL-2 (B세포 림프종 2) 억제제 시장 규모 : 제품별 - 병용 요법에 사용되는 BCL-2 (B세포 림프종 2) 억제제의 시장 규모 - 단독 요법에 사용되는 BCL-2 (B세포 림프종 2) 억제제의 시장 규모 ・세계의 BCL-2 (B세포 림프종 2) 억제제 시장 규모 : 종류별 - 미만성 대세포형 B세포림프종 (DLBCL)에 사용되는 억제제의 시장 규모 - 여포성 림프종에 사용되는 억제제의 시장 규모 - 만성 림프성 백혈병에 사용되는 억제제의 시장 규모 - 맨틀 세포 림프종 (MCL)에 사용되는 억제제의 시장 규모 ・고객 현황 ・지역별 현황 - 북미의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모 - 유럽의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모 - 아시아 태평양의 BCL-2 (B세포 림프종 2) 억제제 시장 규모 - 기타 지역의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모 - 미국의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모 - 캐나다의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모 - 독일의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모 - 영국의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모 - 일본의 BCL-2 (B 세포 림프종 2) 억제제 시장 규모 ・성장 요인/과제/동향 ・기업 현황 ・기업 분석 Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 BCL-2 (B 세포 림프종 2) 억제제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 BCL-2 (B 세포 림프종 2) 억제제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
글로벌 BCL-2(비세포 림프종 2) 억제제 시장에 대한 Technavio의 보고서에 따르면, 이 시장은 2022년부터 2027년까지 1,657.08백만 달러 성장할 것으로 예상되며, 이 기간 동안 연평균 성장률(CAGR)은 12.92%에 이를 것으로 보입니다. 이 보고서는 BCL-2 억제제 시장에 대한 포괄적인 분석을 제공하며, 시장 규모와 예측, 최근 동향, 성장 요인 및 도전 과제, 그리고 약 25개 공급업체에 대한 분석을 포함합니다.
현재 시장 상황, 최신 트렌드와 성장 동력, 전반적인 시장 환경에 대한 최신 분석이 포함되어 있습니다. BCL-2 억제제 시장의 성장은 고령 인구의 증가, 혈액 악성종양에 대한 인식 증대, BCL-2 억제제의 높은 표적 친화도와 특이성 등에 의해 주도되고 있습니다.
BCL-2 억제제 시장은 제품, 유형, 지역에 따라 세분화됩니다. 제품 측면에서는 조합 요법과 단일 요법으로 나눌 수 있으며, 유형은 미만성 대 B 세포 림프종(DLBCL), 여포 림프종, 만성 림프구 백혈병, 맨틀 세포 림프종(MCL)으로 구분됩니다. 지역적으로는 북미, 유럽, 아시아, 그리고 기타 지역(ROW)으로 나뉩니다.
또한, 환자 지원 프로그램의 증가가 향후 몇 년간 BCL-2 억제제 시장 성장의 주요 요인 중 하나로 지목되고 있습니다. 조합 요법의 승인 증가와 혁신적인 제형 개발도 시장 수요에 상당한 영향을 미칠 것입니다.
Technavio의 보고서는 다음과 같은 내용을 포함합니다: BCL-2 억제제 시장 규모, 시장 예측, 산업 분석. 이 보고서는 고객이 시장에서의 위치를 개선할 수 있도록 돕기 위해 여러 주요 BCL-2 억제제 공급업체에 대한 상세한 분석을 제공합니다. 주요 공급업체로는 Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servier, AbbVie Inc. 등이 있습니다.
이 연구는 주요 산업 참여자들로부터의 정보와 함께 1차 및 2차 정보를 객관적으로 결합하여 수행되었습니다. 보고서에는 포괄적인 시장 및 공급업체 환경과 주요 공급업체에 대한 분석이 포함되어 있습니다. Technavio는 시장의 주요 영향력을 파악하여 여러 시장 측면을 제시하며, 신뢰할 수 있는 데이터와 광범위한 연구 결과를 통해 종합적인 분석을 제공합니다.
■ 보고서 목차• 1 요약 • 3 시장 규모 • 4 과거 시장 규모 o 표 34: 병용 요법 – 시장 규모 및 전망 2022-2027 (백만 달러) o 표 56: 만성 림프구성 백혈병 차트 – 2022-2027년 시장 규모 및 전망(백만 달러) o 표 64: 유형별 시장 기회 (백만 달러) o 표 65: 유형별 시장 기회 데이터 표 (백만 달러) • 8 고객 현황 o 표 71: 북미 시장 규모 및 전망 2022-2027년 차트(백만 달러) o 표 83: 기타 지역 (ROW) 시장 차트 – 2022-2027년 시장 규모 및 전망 (백만 달러) o 표 91: 캐나다 시장 규모 및 전망 차트 2022-2027 (백만 달러) o 표 112: 주요 요인의 영향 사업 위험 요소 o 표 121: Abcam plc – 주요 뉴스 o 표 142: 바이오비트(Biorbyt Ltd.) – 개요 o 표 161: 노바티스 주요 제품 및 서비스 첨부 자료: 표 1: 요약 – 시장 개요 차트 첨부자료 17: 글로벌 시장: 전년 대비 성장률 2022-2027 (%) (%) 데이터 표 표 45: 유형별 시장 점유율 데이터표 2022-2027 (%) 첨부자료 70: 지역별 데이터표 IC 비교 o 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market by Geography o Exhibit 05: Executive Summary - Chart on Market Segmentation by Product o Exhibit 06: Executive Summary - Chart on Market Segmentation by Type o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) • 4 Historic Market Size o 4.1 Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021 ($ million) o 4.2 Product Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million) o 4.3 Type Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) • 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 • 6 Market Segmentation by Product o 6.1 Market segments o Exhibit 30: Chart on Product - Market share 2022-2027 (%) o Exhibit 31: Data Table on Product - Market share 2022-2027 (%) o 6.2 Comparison by Product o Exhibit 32: Chart on Comparison by Product o Exhibit 33: Data Table on Comparison by Product o 6.3 Combination therapy - Market size and forecast 2022-2027 o Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%) o 6.4 Monotherapy - Market size and forecast 2022-2027 o Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%) o 6.5 Market opportunity by Product o Exhibit 42: Market opportunity by Product ($ million) o Exhibit 43: Data Table on Market opportunity by Product ($ million) • 7 Market Segmentation by Type o 7.1 Market segments o Exhibit 44: Chart on Type - Market share 2022-2027 (%) o Exhibit 45: Data Table on Type - Market share 2022-2027 (%) o 7.2 Comparison by Type o Exhibit 46: Chart on Comparison by Type o Exhibit 47: Data Table on Comparison by Type o 7.3 Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 o Exhibit 48: Chart on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million) o Exhibit 49: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million) o Exhibit 50: Chart on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%) o Exhibit 51: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%) o 7.4 Follicular lymphoma - Market size and forecast 2022-2027 o Exhibit 52: Chart on Follicular lymphoma - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Data Table on Follicular lymphoma - Market size and forecast 2022-2027 ($ million) o Exhibit 54: Chart on Follicular lymphoma - Year-over-year growth 2022-2027 (%) o Exhibit 55: Data Table on Follicular lymphoma - Year-over-year growth 2022-2027 (%) o 7.5 Chronic lymphocytic leukemia - Market size and forecast 2022-2027 o Exhibit 56: Chart on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Data Table on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million) o Exhibit 58: Chart on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%) o Exhibit 59: Data Table on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%) o 7.6 Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 o Exhibit 60: Chart on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million) o Exhibit 61: Data Table on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million) o Exhibit 62: Chart on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%) o Exhibit 63: Data Table on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%) o 7.7 Market opportunity by Type o Exhibit 64: Market opportunity by Type ($ million) o Exhibit 65: Data Table on Market opportunity by Type ($ million) • 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 67: Chart on Market share by geography 2022-2027 (%) o Exhibit 68: Data Table on Market share by geography 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 69: Chart on Geographic comparison o Exhibit 70: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 Canada - Market size and forecast 2022-2027 o Exhibit 91: Chart on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 92: Data Table on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 93: Chart on Canada - Year-over-year growth 2022-2027 (%) o Exhibit 94: Data Table on Canada - Year-over-year growth 2022-2027 (%) o 9.9 Germany - Market size and forecast 2022-2027 o Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%) o Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%) o 9.10 UK - Market size and forecast 2022-2027 o Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million) o Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%) o Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%) o 9.11 France - Market size and forecast 2022-2027 o Exhibit 103: Chart on France - Market size and forecast 2022-2027 ($ million) o Exhibit 104: Data Table on France - Market size and forecast 2022-2027 ($ million) o Exhibit 105: Chart on France - Year-over-year growth 2022-2027 (%) o Exhibit 106: Data Table on France - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity by geography o Exhibit 107: Market opportunity by geography ($ million) o Exhibit 108: Data Tables on Market opportunity by geography ($ million) • 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 109: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends • 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 111: Overview on factors of disruption o 11.4 Industry risks o Exhibit 112: Impact of key risks on business • 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 113: Vendors covered o 12.2 Market positioning of vendors o Exhibit 114: Matrix on vendor position and classification o 12.3 AbbVie Inc. o Exhibit 115: AbbVie Inc. - Overview o Exhibit 116: AbbVie Inc. - Product / Service o Exhibit 117: AbbVie Inc. - Key news o Exhibit 118: AbbVie Inc. - Key offerings o 12.4 Abcam plc o Exhibit 119: Abcam plc - Overview o Exhibit 120: Abcam plc - Product / Service o Exhibit 121: Abcam plc - Key news o Exhibit 122: Abcam plc - Key offerings o 12.5 Amgen Inc. o Exhibit 123: Amgen Inc. - Overview o Exhibit 124: Amgen Inc. - Product / Service o Exhibit 125: Amgen Inc. - Key offerings o 12.6 Ascentage Pharma Group International o Exhibit 126: Ascentage Pharma Group International - Overview o Exhibit 127: Ascentage Pharma Group International - Product / Service o Exhibit 128: Ascentage Pharma Group International - Key offerings o 12.7 AstraZeneca Plc o Exhibit 129: AstraZeneca Plc - Overview o Exhibit 130: AstraZeneca Plc - Product / Service o Exhibit 131: AstraZeneca Plc - Key news o Exhibit 132: AstraZeneca Plc - Key offerings o 12.8 BeiGene Ltd. o Exhibit 133: BeiGene Ltd. - Overview o Exhibit 134: BeiGene Ltd. - Business segments o Exhibit 135: BeiGene Ltd. - Key offerings o Exhibit 136: BeiGene Ltd. - Segment focus o 12.9 Bio Techne Corp. o Exhibit 137: Bio Techne Corp. - Overview o Exhibit 138: Bio Techne Corp. - Business segments o Exhibit 139: Bio Techne Corp. - Key news o Exhibit 140: Bio Techne Corp. - Key offerings o Exhibit 141: Bio Techne Corp. - Segment focus o 12.10 Biorbyt Ltd. o Exhibit 142: Biorbyt Ltd. - Overview o Exhibit 143: Biorbyt Ltd. - Product / Service o Exhibit 144: Biorbyt Ltd. - Key offerings o 12.11 Bristol Myers Squibb Co. o Exhibit 145: Bristol Myers Squibb Co. - Overview o Exhibit 146: Bristol Myers Squibb Co. - Product / Service o Exhibit 147: Bristol Myers Squibb Co. - Key news o Exhibit 148: Bristol Myers Squibb Co. - Key offerings o 12.12 F. Hoffmann La Roche Ltd. o Exhibit 149: F. Hoffmann La Roche Ltd. - Overview o Exhibit 150: F. Hoffmann La Roche Ltd. - Business segments o Exhibit 151: F. Hoffmann La Roche Ltd. - Key news o Exhibit 152: F. Hoffmann La Roche Ltd. - Key offerings o Exhibit 153: F. Hoffmann La Roche Ltd. - Segment focus o 12.13 Merck and Co. Inc. o Exhibit 154: Merck and Co. Inc. - Overview o Exhibit 155: Merck and Co. Inc. - Business segments o Exhibit 156: Merck and Co. Inc. - Key news o Exhibit 157: Merck and Co. Inc. - Key offerings o Exhibit 158: Merck and Co. Inc. - Segment focus o 12.14 Novartis AG o Exhibit 159: Novartis AG - Overview o Exhibit 160: Novartis AG - Business segments o Exhibit 161: Novartis AG - Key offerings o Exhibit 162: Novartis AG - Segment focus o 12.15 Santa Cruz Biotechnology Inc. o Exhibit 163: Santa Cruz Biotechnology Inc. - Overview o Exhibit 164: Santa Cruz Biotechnology Inc. - Product / Service o Exhibit 165: Santa Cruz Biotechnology Inc. - Key offerings o 12.16 Seagen Inc. o Exhibit 166: Seagen Inc. - Overview o Exhibit 167: Seagen Inc. - Product / Service o Exhibit 168: Seagen Inc. - Key offerings o 12.17 Servier o Exhibit 169: Servier - Overview o Exhibit 170: Servier - Business segments o Exhibit 171: Servier - Key offerings o Exhibit 172: Servier - Segment focus • 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 173: Inclusions checklist o Exhibit 174: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 175: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 176: Research methodology o Exhibit 177: Validation techniques employed for market sizing o Exhibit 178: Information sources o 13.5 List of abbreviations o Exhibit 179: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market by Geography Exhibits5: Executive Summary - Chart on Market Segmentation by Product Exhibits6: Executive Summary - Chart on Market Segmentation by Type Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Product Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Type Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Product - Market share 2022-2027 (%) Exhibits31: Data Table on Product - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Product Exhibits33: Data Table on Comparison by Product Exhibits34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%) Exhibits42: Market opportunity by Product ($ million) Exhibits43: Data Table on Market opportunity by Product ($ million) Exhibits44: Chart on Type - Market share 2022-2027 (%) Exhibits45: Data Table on Type - Market share 2022-2027 (%) Exhibits46: Chart on Comparison by Type Exhibits47: Data Table on Comparison by Type Exhibits48: Chart on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million) Exhibits49: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million) Exhibits50: Chart on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%) Exhibits51: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%) Exhibits52: Chart on Follicular lymphoma - Market size and forecast 2022-2027 ($ million) Exhibits53: Data Table on Follicular lymphoma - Market size and forecast 2022-2027 ($ million) Exhibits54: Chart on Follicular lymphoma - Year-over-year growth 2022-2027 (%) Exhibits55: Data Table on Follicular lymphoma - Year-over-year growth 2022-2027 (%) Exhibits56: Chart on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million) Exhibits57: Data Table on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million) Exhibits58: Chart on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%) Exhibits59: Data Table on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%) Exhibits60: Chart on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million) Exhibits61: Data Table on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million) Exhibits62: Chart on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%) Exhibits63: Data Table on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%) Exhibits64: Market opportunity by Type ($ million) Exhibits65: Data Table on Market opportunity by Type ($ million) Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits67: Chart on Market share by geography 2022-2027 (%) Exhibits68: Data Table on Market share by geography 2022-2027 (%) Exhibits69: Chart on Geographic comparison Exhibits70: Data Table on Geographic comparison Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits91: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibits92: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibits93: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibits94: Data Table on Canada - Year-over-year growth 2022-2027 (%) Exhibits95: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibits96: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibits97: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibits98: Data Table on Germany - Year-over-year growth 2022-2027 (%) Exhibits99: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibits100: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibits101: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibits102: Data Table on UK - Year-over-year growth 2022-2027 (%) Exhibits103: Chart on France - Market size and forecast 2022-2027 ($ million) Exhibits104: Data Table on France - Market size and forecast 2022-2027 ($ million) Exhibits105: Chart on France - Year-over-year growth 2022-2027 (%) Exhibits106: Data Table on France - Year-over-year growth 2022-2027 (%) Exhibits107: Market opportunity by geography ($ million) Exhibits108: Data Tables on Market opportunity by geography ($ million) Exhibits109: Impact of drivers and challenges in 2022 and 2027 Exhibits110: Overview on Criticality of inputs and Factors of differentiation Exhibits111: Overview on factors of disruption Exhibits112: Impact of key risks on business Exhibits113: Vendors covered Exhibits114: Matrix on vendor position and classification Exhibits115: AbbVie Inc. - Overview Exhibits116: AbbVie Inc. - Product / Service Exhibits117: AbbVie Inc. - Key news Exhibits118: AbbVie Inc. - Key offerings Exhibits119: Abcam plc - Overview Exhibits120: Abcam plc - Product / Service Exhibits121: Abcam plc - Key news Exhibits122: Abcam plc - Key offerings Exhibits123: Amgen Inc. - Overview Exhibits124: Amgen Inc. - Product / Service Exhibits125: Amgen Inc. - Key offerings Exhibits126: Ascentage Pharma Group International - Overview Exhibits127: Ascentage Pharma Group International - Product / Service Exhibits128: Ascentage Pharma Group International - Key offerings Exhibits129: AstraZeneca Plc - Overview Exhibits130: AstraZeneca Plc - Product / Service Exhibits131: AstraZeneca Plc - Key news Exhibits132: AstraZeneca Plc - Key offerings Exhibits133: BeiGene Ltd. - Overview Exhibits134: BeiGene Ltd. - Business segments Exhibits135: BeiGene Ltd. - Key offerings Exhibits136: BeiGene Ltd. - Segment focus Exhibits137: Bio Techne Corp. - Overview Exhibits138: Bio Techne Corp. - Business segments Exhibits139: Bio Techne Corp. - Key news Exhibits140: Bio Techne Corp. - Key offerings Exhibits141: Bio Techne Corp. - Segment focus Exhibits142: Biorbyt Ltd. - Overview Exhibits143: Biorbyt Ltd. - Product / Service Exhibits144: Biorbyt Ltd. - Key offerings Exhibits145: Bristol Myers Squibb Co. - Overview Exhibits146: Bristol Myers Squibb Co. - Product / Service Exhibits147: Bristol Myers Squibb Co. - Key news Exhibits148: Bristol Myers Squibb Co. - Key offerings Exhibits149: F. Hoffmann La Roche Ltd. - Overview Exhibits150: F. Hoffmann La Roche Ltd. - Business segments Exhibits151: F. Hoffmann La Roche Ltd. - Key news Exhibits152: F. Hoffmann La Roche Ltd. - Key offerings Exhibits153: F. Hoffmann La Roche Ltd. - Segment focus Exhibits154: Merck and Co. Inc. - Overview Exhibits155: Merck and Co. Inc. - Business segments Exhibits156: Merck and Co. Inc. - Key news Exhibits157: Merck and Co. Inc. - Key offerings Exhibits158: Merck and Co. Inc. - Segment focus Exhibits159: Novartis AG - Overview Exhibits160: Novartis AG - Business segments Exhibits161: Novartis AG - Key offerings Exhibits162: Novartis AG - Segment focus Exhibits163: Santa Cruz Biotechnology Inc. - Overview Exhibits164: Santa Cruz Biotechnology Inc. - Product / Service Exhibits165: Santa Cruz Biotechnology Inc. - Key offerings Exhibits166: Seagen Inc. - Overview Exhibits167: Seagen Inc. - Product / Service Exhibits168: Seagen Inc. - Key offerings Exhibits169: Servier - Overview Exhibits170: Servier - Business segments Exhibits171: Servier - Key offerings Exhibits172: Servier - Segment focus Exhibits173: Inclusions checklist Exhibits174: Exclusions checklist Exhibits175: Currency conversion rates for US$ Exhibits176: Research methodology Exhibits177: Validation techniques employed for market sizing Exhibits178: Information sources Exhibits179: List of abbreviations |
| ※참고 정보 BCL-2 억제제는 세포 사멸을 조절하는 단백질인 BCL-2의 기능을 억제하는 약물로, 주로 암 치료에 사용된다. BCL-2 단백질은 세포의 생존을 촉진하고, 따라서 암세포의 생존율을 높이는 역할을 한다. BCL-2는 비정상 세포뿐만 아니라 일부 건강한 세포에서도 나타나지만, 암세포에서는 특히 과발현되는 경향이 있다. 이러한 과발현은 종양의 성장, 전이 및 화학치료에 대한 저항성과 관련이 있어, BCL-2 관련 경로를 표적하는 치료법이 개발되었다. BCL-2 억제제는 주로 호지킨 림프종, 비호지킨 림프종, 만성 림프구 백혈병과 같은 혈액암 치료에 사용된다. 대표적인 BCL-2 억제제로는 베네토클락스(Venetoclax)가 있다. 이 약물은 BCL-2에 선택적으로 결합하여 그 기능을 차단함으로써 세포자살(apoptosis)을 유도한다. 이는 암세포가 생존할 수 없는 환경을 조성하게 되어, 종양의 성장을 억제한다. BCL-2 억제제가 효과를 발휘하기 위해서는 다른 항암제와 병용하는 경우가 많다. 예를 들어, 전통적인 화학요법이나 면역요법과 조합하여 사용함으로써 치료 효과를 증대시키고, 내성을 극복하는 데 도움을 줄 수 있다. 더욱이 BCL-2 억제제는 특정 유전자 변이를 가진 종양에서 특히 효과적이며, 개인 맞춤형 치료 접근 방식의 하나로 부각되고 있다. BCL-2 억제제의 연구 개발 과정에서는 합성 화합물뿐만 아니라, 단백질 상호작용을 저해하는 다양한 기법이 활용된다. 최근의 연구에서는 BCL-2의 구조 분석 및 표적화 접근이 중요하게 다뤄지고 있다. 이와 함께 전이성 종양이나 다양한 저항성 암세포를 대상으로 한 치료 연구가 진행되고 있으며, 새로운 BCL-2 억제제를 찾기 위한 노력도 계속되고 있다. BCL-2 억제제의 장점에도 불구하고, 부작용이 발생할 수 있으며, 특히 감염의 위험 증가, 혈소판 감소증, 간 기능 이상 등과 같은 혈액학적 부작용이 보고되고 있다. 따라서 이 약물의 사용은 전문적인 관리 하에 이루어져야 한다. 여러 임상시험이 진행 중이며, 이로 인해 새로운 용도를 발견하거나, 기존 치료법과의 조합을 통해 치료 성과를 극대화하는 방법이 모색되고 있다. 종합적으로 볼 때, BCL-2 억제제는 암 치료에 있어 중요한 혁신적 접근법으로 자리잡고 있으며, 향후 지속적인 연구와 개발이 이 분야에서 중요한 진전을 이룰 것으로 기대된다. 이러한 약물은 환자의 삶의 질을 개선하고, 암 치료의 새로운 가능성을 여는 중요한 역할을 할 것으로 예상된다. |
| ※본 조사보고서 [세계의 BCL-2 (B세포 림프종 2) 억제제 시장 (2023년~2027년)] (코드 : IRTNTR72723-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 BCL-2 (B세포 림프종 2) 억제제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |

